Cutaneous gamma/delta T-cell lymphoma treated with retinoid and narrowband ultraviolet B

Nakashima, Hiroko; Sugaya, Makoto; Minatani, Yosaku; Ohmatsu, Hanako; Asano, Naoki; Fujimoto, Manabu; Kikuchi, Kenji; Ihn, H.; Tamaki, Kunihiko

doi:10.1111/j.1365-2230.2009.03296.x

Cited by 17 publications

(19 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More studies and observations are warranted to shed light on the correct classifications of such cases to establish whether they represent a variant of MF or a more indolent form of epidermotropic or folliculotropic CGD-TCL for which less aggressive treatment may be effective. 10,26,31,32 …”

Section: Discussionmentioning

confidence: 99%

“…10 Response of CGD-TCL with epidermotropic, dermal, and subcutaneous infiltrates to radiotherapy, retinoid, and UV-B narrowband was observed in a 62-year-old woman. 26 No matter what name is attached to similar cases, it will be important to identify prognostic and therapeutic markers for these rare CTCL. A high number of PD-1-positive lymphocytes were found in case 1.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Two Cases of Primary Cutaneous Lymphoma With a γ/δ+ Phenotype and an Indolent Course

Kempf¹,

Kazakov

Scheidegger

et al. 2014

The American Journal of Dermatopathology

View full text Add to dashboard Cite

Cutaneous [gamma]/[delta]+ T-cell lymphoma (CGD-TCL) is a rare but aggressive lymphoma associated with a poor prognosis in most patients. The clinicopathological spectrum is variable including predominantly epidermotropic infiltrates manifesting with patches and plaques or tumors with dermal and/or subcutaneous infiltrates. The diagnosis of CGD-TCL requires the demonstration of a [gamma]/[delta]+ phenotype by immunohistochemistry. We report 2 patients with epidermotropic cutaneous T-cell lymphomas displaying a [gamma]/[delta]+ phenotype, but exhibiting an indolent course. In one patient, the clinical presentation was similar to mycosis fungoides in patch and plaque stage, but recurrent blister formation within the lesions was observed accompanied by fever and arthralgias, whereas the second patient presented with 2 localized erosive plaques on the left temple and dense epidermotropic and dermal diffuse and folliculotropic infiltrates of atypical small-to-medium-sized lymphocytes. exhibiting an indolent course. In one patient, the clinical presentation was similar to mycosis fungoides in patch and plaque stage, but recurrent blister formation within the lesions was observed accompanied by fever and arthralgias, whereas the second patient presented with 2 localized erosive plaques on the left temple and dense epidermotropic and dermal diffuse and folliculotropic infiltrates of atypical small-tomedium-sized lymphocytes. These cases corroborate the view that expression of a g/d+ phenotype in cutaneous T-cell lymphomas per se does not portend a worse prognosis and that CGD-TCL may represent a clinically and prognostically heterogeneous group.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Two Cases of Primary Cutaneous Lymphoma With a γ/δ+ Phenotype and an Indolent Course

Kempf¹,

Kazakov

Scheidegger

et al. 2014

The American Journal of Dermatopathology

View full text Add to dashboard Cite

show abstract

“…Among cases confirmed to be PCGD-TCL on the basis of TCR PCR, 1 long-term survivor was treated with CHOP, then interferon > and isoretinoin, then staurosporine 29 ; a second was refractory to a series of treatment including interferon >, chemotherapy, methotrexate, and asparaginase, before ultimately undergoing allogeneic stem cell transplantation, 30 and a third received electron beam therapy, retinoid therapy (etretinate), and narrow-band UVB. 33 Other favorable outcomes are also reported as case reports or small, potentially heterogeneous case series. Favorable outcomes have also been reported in a case series of SPTCL treated with bexarotene (overall response rate, 82%), although only 2 of the patients had definite CGD-TCL as opposed to the >/A subtype.…”

Section: The Primary Cutaneous T-cell Lymphomasmentioning

confidence: 85%

Management of the Cutaneous Peripheral T-Cell Lymphomas

Choi

Lechowicz²

2012

The Cancer Journal

View full text Add to dashboard Cite

The cutaneous T-cell lymphomas are a heterogeneous collection of many biologically and clinically distinct cancers. The World Health Organization 2008 reclassification of cutaneous lymphomas delineated provisional entities that were previously classified simply as primary cutaneous peripheral T-cell lymphoma not otherwise specified. Because of the relative rarity of cases, standard treatment recommendations and algorithms are lacking. However, identification of these subtypes is important as they can have vastly different clinical outcomes. Furthermore, cytokine treatments effective in classic mycosis fungoides or Sezary syndrome not only are ineffective, but also may exacerbate certain subtypes. The aim of this review was to summarize the biological bases of the recently defined entities, reinforce the importance of acute clinical/pathologic diagnosis, and propose treatment strategies based on the available data.

show abstract

“…The prognosis of y8 T-cell lymphoma is usually very poor. However, cases with more indolent clinical courses have been reported (6,7). So far, not all cases with cutaneous lymphoma have been examined for TCR aß or yô expression because immunohistochemistry using fi-ozen samples or fiow cytometric analysis has been necessary.…”

Section: Discussionmentioning

confidence: 97%